ArticleCell communication and signaling : CCS2026
Mechanism of L-Buthionine-(S,R)-sulfoximine-induced ferroptotic cell death in mouse hippocampal neuronal cells.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Recent studies have revealed that accumulation of cellular nitric oxide (NO) resulting from protein disulfide isomerase (PDI)-catalyzed dimerization (i.e., catalytic activation) of nitric oxide synthase (NOS) is a pivotal upstream event in the induction of ferroptosis. L-Buthionine-(S,R)-sulfoximine (BSO), an inhibitor of the γ-glutamylcysteine synthase, can induce cellular glutathione depletion and ferroptosis. The present study aims to investigate whether PDI-centered signaling axis also mediates BSO-induced ferroptosis. Using the HT22 mouse hippocampal neurons as an in-vitro model, we found that BSO-induced glutathione depletion is associated with the oxidative activation of PDI, and the activated PDI mediates ferroptosis by catalyzing the dimerization of the inducible NOS (iNOS). iNOS dimerization then leads to the accumulation of cellular NO, which subsequently results in the accumulation of cellular ROS and lipid peroxides as well as mitochondrial ROS and lipid peroxides, and ultimately, oxidative ferroptosis. Pharmacological inhibition of PDI’s enzymatic activity or selective PDI knockdown can effectively abrogate BSO-induced ferroptosis. Similarly, selective inhibition of other signaling components along the PDI–iNOS–NO–ROS axis also confers strong protection against BSO-induced ferroptosis. In addition, BSO-induced ferroptosis can be selectively enhanced by chemicals that facilitate PDI activation or PDI-mediated iNOS dimerization or NO accumulation. The results of this study demonstrate that the PDI‒iNOS‒NO‒ROS signaling axis plays a pivotal role in BSO-induced ferroptosis in a cell culture model, and also offer strategies for the selective manipulation (enhancement or suppression) of ferroptosis by targeting PDI or its downstream signaling elements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.